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MODIFIED FRAILTY INDEX PREDICTS MORTALITY AND
ADVERSE OUTCOMES IN PATIENTS UNDERGOING RENAL
SURGERY: ANALYSIS OF THE NATIONAL SURGICAL QUALITY
IMPROVEMENT PROGRAM (NSQIP) DATABASE
Jamie S. Pak*, Danny Lascano, Julia B. Finkelstein, Mark V. Silva,
G. Joel DeCastro, James M. McKiernan, Mitchell C. Benson,
New York, NY
INTRODUCTION AND OBJECTIVES: Frailty, a concept of
growing interest in light of the aging population, describes the gradual
loss of physical and mental capacity. Practically, an objective measure
of frailty can replace the often subjective assessment of a patient’s
ability to tolerate a surgical intervention. We propose that a modified
version (mFI) of the Canadian Study of Health and Aging Frailty Index
(CSHA-FI) can predict 30-day mortality and other adverse outcomes in
patients undergoing renal surgery.
METHODS: We accessed the NSQIP database for all partial,
simple, and radical nephrectomies as well as nephroureterectomies
performed from 2005 to 2012. The mFI was calculated as the proportion
of the following 11 CHSA-FI risk factors present in each patient: dia-
betes mellitus; dependent functional status; history of severe COPD or
current pneumonia; CHF within 30 days before surgery; history of MI 6
months prior to surgery; previous PCI, cardiac surgery, or history of
angina within 1 month before surgery; hypertension requiring medica-
tion; peripheral vascular disease or rest pain; impaired sensorium;
history of TIA or CVA; history of CVA with neurologic deficit. Primary
outcome was 30-day mortality. Chi-square analysis ( Fisher’s exact
test) and Kruskal-Wallis test were performed for statistical analysis.
RESULTS: A total of 8,542 patients were identified. There were
65 deaths, 52 MIs, 41 cardiac arrests requiring CPR, 100 DVT/PEs, 162
SSIs, 145 UTIs, 43 instances of septic shock, 76 instances of ventilator
dependence >48 hours, 118 unplanned intubations, and 85 episodes of
acute renal failure (ARF) requiring dialysis. Higher mFI was strongly
associated with 30-day mortality, septic shock, ventilator dependence,
unplanned intubation, Clavien IV complications, and any adverse
outcome after renal surgery (all p<0.0005). mFI was also associated
with MI, UTI, and ARF (p<0.05). Higher mFI correlated with increasing
mean ranks in operative time (p¼0.032) and in hospital length of stay
(p<0.0005). Odds ratio of 30-day mortality in patients with mFI 0.27
was 6.47 (95% CI 1.96-21.30, p<0.0021).
CONCLUSIONS: PatientswithmFI0.27wereover6 timesmore
likely to diewithin 30days after renal surgery.mFIwas also associatedwith
numerousother significantperioperativeoutcomes.These findingssupport
the utility of this simple tool as a predictor of adverse outcomes in patients
undergoing renal surgery and potentially urologic surgery in general.
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HOW A DONOR NEPHRECTOMY POPULATION CAN HELP
CLARIFY THE EFFECTS OF WARM RENAL ISCHEMIA DURING
PARTIAL NEPHRECTOMY
Roger Li, Herbert C. Ruckle, Muhannad Alsyouf*, Michelle Lightfoot,
Jared Schober, David Tryon, Kristene Myklak, David Culpepper,
Daniel Faaborg, Phillip Stokes, Javier L. Arenas, D. Duane Baldwin,
Loma Linda, CA
INTRODUCTION AND OBJECTIVES: The most important
modifiable risk factors for kidney function after partial nephrectomy (PN)are the quantity of parenchyma removed and the length of warm
ischemia time (WIT) although the relative importance of these two
factors has been debated. In this study, the effects of WIT on renal
function were investigated by comparing PN patients to completely
healthy patients undergoing donor nephrectomy (DN).
METHODS: A retrospective review was performed of 119 PN
and 250 DN patients at a single academic institution. Baseline char-
acteristics, WIT, and follow-up serum creatinine (sCr) at discharge, 1-
7months and at last follow-up were compared. Estimated GFR (eGFR)
was calculated using sCr and the Modification of Diet on Renal Disease
(MDRD) formula. Data was analyzed using the Mann-Whitney U and
Chi-square tests as appropriate.
RESULTS: The DN patients were younger (37.5 vs. 60.8;
p<0.01), had lower BMI (26.6 vs. 30.9; p<0.01), lower ASA scores
(p<0.01) and higher preoperative eGFR (101.7 vs. 78.4; p<0.01). In
the PN cohort, the median tumor size was 3.6 cm and mean WIT
was 27.8 minutes. DN patients were found to have greater eGFR
decline upon discharge (-42.7% vs. -1.5%, p<0.01), at 1-7 mos
postoperatively (-36.9% vs. -6.4%; p<0.01) and at the latest follow-
up (-36.3% vs. -2.4%; p<0.01). The percentage decrease in eGFR
was also significantly greater in donor nephrectomy patients than
partial nephrectomy patients with WIT > 30 minutes at all time
points including discharge (-42.7% vs. -4.1%; p<0.01) at 1-7 mos
(-36.9% vs. -3.8%; p<0.01) and at latest follow-up (-36.3% vs.
-6.9%; p<0.01).
CONCLUSIONS: Despite being younger and healthier, the
donors had a much greater decrease in GFR than all PN patients
including those with > 30 min WIT. This dramatic benefit of partial
nephrectomy compared with radical nephrectomy in all patients em-
phasizes the benefit to GFR derived from renal parenchymal preser-
vation. Surgeons should utilize warm renal ischemia when indicated if it
facilitates the preservation of renal parenchyma.
Source of Funding: noneMP63-03
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INTRODUCTION AND OBJECTIVES: In a recent subanalysis
of 514 patients included in the EORTC randomized trial 30904, the
incidence of End Stage Renal Disease (ESRD) was nearly identical
between patients treated with nephron sparing surgery (NSS) or radical
nephrectomy (RN). In the current paper, we aimed to report the rate and
the predictors of ESRD after NSS vs. RN after accounting for clinical
characteristics, comorbidities and individual patients’ cardiovascu-
lar risk.
METHODS: A multi-institutional collaboration among five Ter-
tiary Care Centers allowed collecting 2029 patients with a clinical T1a-
T1b renal mass. Patients underwent RN (n¼693, 34.2%) or NSS
(n¼1336, 65.8%) and showed normal estimated glomerular filtration
rates (eGFR) before surgery (defined as a pre-operative eGFR60ml/
min/1.73m2). Descriptive, univariable and multivariable Cox regression
analyses were used to predict the risk of ESRD (defined as post-
operative eGFR <15ml/min/1.73m2). To adjust for inherent baseline
differences among patients, we included as covariates: age, pre-oper-
ative GFR, clinical tumor size, hypertension (none vs. yes vs. controlled
by medical therapy), diabetes, baseline Charlson comorbidity index
(CCI), body mass index and smoker status.
RESULTS: Median preoperative GFR was 90ml/min/1.73m2
(interquartile range, IQR 79-99). Median age was 61 yrs (IQR 52-69)
e790 THE JOURNAL OF UROLOGY Vol. 193, No. 4S, Supplement, Monday, May 18, 2015and median clinical tumor size 3.5 cm (IQR 2.5-5). Overall, 10.0% vs.
18.2% vs. 21.3% of the patients had diabetes, uncontrolled or hyper-
tension controlled by medical therapy, respectively.
The 5 yr, 10 yr and 15 yr ESRD rates after surgery were 1.6%,
2.6% and 2.6% for NSS vs. 2.1%, 2.7% and 5.1% for RN, respec-
tively (p¼0.5). At multivariable analyses, after accounting for clinical
characteristics, comorbidities and individual cardiovascular risk,
patients with hypertension not controlled by medical therapy (HR
4.2, p¼0.02) and those with more than 2 comorbidities (HR 8.5,
p¼0.009) showed significantly higher risk to develop ESRD. Patients
who underwent NSS showed virtually the same risk to develop
ESRD relative to their RN-treated counterparts (HR 1.04, p¼0.9).
However, mean time to ESRD was significantly higher in patients
treated with NSS relative to RN (85 vs. 43 months, bootstrapped p-
value¼0.04).
CONCLUSIONS: Roughly 2% of the patients with normal GFR
before kidney surgery will develop ESRD, with virtually no difference
between those treated with NSS or RN. Interestingly, NSS showed a
statistically significant effect in delaying the onset of ESRD relative
to RN.
Source of Funding: NoneMP63-04
CLINICAL AND PATHOLOGICAL LYMPH NODE PROGRESSION IN
PATIENTS WITH A CT1-T2 N0 M0 RENAL MASS: SHALL WE
FOREVER DISCARD THE USE OF LYMPH NODE DISSECTION IN
LOW RISK PATIENTS?
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INTRODUCTION AND OBJECTIVES: The EORTC random-
ized trial has demonstrated a low rate of lymph node invasion (LNI) and
no benefit in terms of survival in patients with low risk renal cell carci-
noma (RCC). Although clinically at low risk, it is plausible that even a
subgroup of those patients may harbour a disease with a predilection for
LNI that may deserve a standard lymph node dissection at the time of
surgery.
METHODS: In 2010 patients with a clinical T1-T2N0M0 renal
mass treated with nephrectomy, we considered as a mutual endpoint
the presence of lymph node invasion (LNI) and/or lymph node (LN)
progression during the follow-up. Nodal progression was defined as
the onset of a new clinically detected lymphadenopathy (>10 mm) in
the retroperitoneal lymphatic area with associated systemic pro-
gression and/or histological confirmation. Cubic spline and regres-
sion analyses were used to describe clinical and pathological
characteristics of patients who developed LNI and/or LN progression
(age, body mass index, tumor size, T stage, albumin, LDH, lym-
phocytes, monocytes, calcium, creatinine, haemoglobin, and plate-
lets levels).
RESULTS: Clinical T stage resulted cT1a, cT1b, cT2a and
cT2b in 1010 (50.2%), 686 (34.1%), 233 (11.6%) and 81 (4.0%) pa-
tients, respectively. In 640 patients (36.3%), LND was performed. As
regards pathological characteristics, upstaging to pT3a or higher was
found in 228 patients (11.3%). Fuhrman grade resulted 1 vs. 2 vs. 3 vs.
4 in 245 (12.2%) vs. 1151 (57.3%) vs. 306 (15.2%) vs. 24 (1.2%),
respectively. In only 14 cases (0.8%), patients showed LNI at surgery.
During the follow-up, 23 (1.1%) of the patients experienced LN pro-
gression. Combining the two endpoints, 36 (1.8%) of the patients
showed predilection for lymph node invasion (LNI and/or LN progres-
sion during the follow-up). LNI and/or LN progression was found in 0.6%
vs. 1.9% vs. 3.9% vs. 9.9% cases of cT1a vs. cT1b vs. cT2a vs. cT2b,
respectively (p<0.001). Clinical tumor size showed a linear correlation
with the risk of LNI and/or LN progression (OR 1.27 95%CI 1.16-1.38,
p<0.001). LNI and/or LN progression was evident in 0% vs. 0.4% vs.
1.6% vs. 4.2% vs. 16.7% cases of benign vs. G1 vs. G2 vs. G3 vs. G4,
respectively (p<0.001).CONCLUSIONS: LNI and/or LN progression risk is a rare entity
(<2%) when patients with a low risk renal mass (T1-T2 N0 M0) undergo
surgery. Clinical tumor size is the most informative clinical (preoperative)
predictor of LNI and/or LN progression althoughmore accurate biomarkers
are desirable to better identify low risk patients who may benefit from LND.
Source of Funding: NoneMP63-05
ROBOTIC INFERIOR VENA CAVA THROMBECTOMY AND
RADICAL NEPHRECTOMY FOR LEVEL II AND III THROMBI: THE
USC EXPERIENCE
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INTRODUCTION AND OBJECTIVES: Renal cell carcinoma
(RCC) with tumor thrombus with extension into the inferior vena cava
(IVC) is present in 4-10% of cases. Level II and III tumor thrombus
inferior vena cava (IVC) extension have been previously viewed as a
contradiction to the minimally invasive approach. With advances in ro-
botic renal surgery and surgical techniques these challenging cases are
now being explored. We report our initial experience with level II and III
tumor thrombi for renal cell carcinomas with IVC involvement.
METHODS: An Institutional review board approved renal
database was used to prospectively accrue data on those patients with
RCC with level II and III thrombi. Patient demographics, tumor and
thrombi characteristics, perioperative, postoperative and oncologic
follow up data were retrospectively analyzed.
RESULTS: A total of 11 patients, 6 with level II and 5 with level
III are included in the study. Mean age and body mass index were 67.8
yrs and 31.3 kg/m2. Seven renal masses were right sided and 4 were
left sided tumors. Median tumor size and thrombi length were 8 cm and
4.5 cm. Median size of the level II thrombi and level III thrombi were 3.3
and 5.4 cm respectively. Eight cases underwent preoperative emboli-
zation. There was a mean of 2.3 and 1.6 lumbar veins taken within the
two groups and those that were level III thrombi had a mean of 2.6
hepatic veins taken for proximal control of the IVC. Suprarenal caval
control was utilized in all 11 cases. Median operative time and esti-
mated blood loss was 280 minutes and 300 ml. Four patients required
blood transfusions during the perioperative course. Median length of
hospital stay was 4 days. Mean follow-up is 15.3 months. One patient
has metastatic disease currently being treated on a clinical trial and
another patient has a single stable lung metastatic deposit. The
remaining 9 patients show no evidence of disease.
CONCLUSIONS: Robotic IVC thrombectomy and radical ne-
phrectomy for renal cell carcinoma with tumor thrombus is a very
challenging and demanding surgery with high risks to perform. With
appropriate surgical planning and technical expertise these procedures
can be performed safely as well as gain from the benefits of the mini-
mally invasive approach. Longer follow-up is necessary to confirm
oncologic outcomes.
Source of Funding: NONEMP63-06
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INTRODUCTION AND OBJECTIVES: The trifecta of oncology,
complications and functional outcome has been proposed as a
